EWTX

SEC source: 0001655016-26-000006 · primarydocument.xml · nonDerivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,141

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 7

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,625

F7 · shares: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.

F8 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 9

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-08-12

F7 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 8

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2036-08-12

F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 7

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,094

Underlying: Common Stock · 7,031 shares

Expires 2035-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001853529-26-000002 · primarydocument.xml · derivative · entry 6

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 5

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,466

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

SEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 4

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,856

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,129

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,367

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853529-26-000002 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,336

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 10

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-08-12

F9 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 9

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-08-12

F8 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 8

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 7,500 shares

Expires 2035-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 7

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 6

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,826

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 5

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,301

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.415 to $44.50, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 4

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,451

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 3

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,755

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.30 to $44.145, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 2

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,926

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 1

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001705477-26-000001 · primarydocument.xml · derivative · entry 2

Nofi Michael · CIK 0001705477 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,750

Underlying: Common Stock · 48,750 shares

Expires 2036-08-12

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001705477-26-000001 · primarydocument.xml · derivative · entry 1

Nofi Michael · CIK 0001705477 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,375

Underlying: Common Stock · 24,375 shares

Expires 2036-08-12

F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 11

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-08-12

F12 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 10

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2036-08-12

F11 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 9

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,094

Underlying: Common Stock · 7,031 shares

Expires 2035-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001644087-26-000005 · primarydocument.xml · derivative · entry 8

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 6

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,544

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F6 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 5

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,344

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 4

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,448

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 3

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,227

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 2

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001644087-26-000005 · primarydocument.xml · nonDerivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 10

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-08-12

F9 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 9

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2036-08-12

F8 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 8

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,157

Underlying: Common Stock · 6,718 shares

Expires 2035-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 7

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,563

Underlying: Common Stock · 5,781 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 6

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,697

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 5

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,116

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 4

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,215

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,274

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 9

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-08-12

F8 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 8

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-08-12

F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

SEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 7

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,625

Underlying: Common Stock · 21,875 shares

Expires 2035-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

SEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 6

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,938

Underlying: Common Stock · 17,969 shares

Expires 2034-08-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

SEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 5

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,488

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 4

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,401

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 3

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,677

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.